Heidi Overton, President Trump’s nominee to lead the FDA, reaffirmed in a Senate hearing that the MMR vaccine and the abortion drug mifepristone are safe and effective, while declining to directly endorse whether the president could be wrong. Senators pressed her on vaccine policy, guidance alignment, and how she would handle politically sensitive disputes. The exchange also highlighted the broader regulatory risk environment: the nomination arrives amid concerns about FDA stability and perceptions of politicized decision-making. Overton’s stated focus included speeding medical research and optimizing clinical development processes to compete with faster-moving biotech ecosystems abroad. For the biotech industry, the hearing matters because commissioner-level priorities can translate into practical changes in clinical trial timelines, guidance interpretation, and how regulators manage contentious policy intersections.